| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-06-14 | Toujeo® (insulin glargine [rDNA origin]) | type 2 diabetes |
3 | Sanofi (France) | Metabolic diseases |
| 2014-06-14 | Notch1 Diagnostic Assay (companion diagnostic to identify patients whose cancer may be more likely to benefit from treatment with anti-Notch1 antibody, OMP-52M51) | hematologic malignancies |
OncoMed Pharmaceuticals (USA) | Cancer - Oncology | |
| 2014-06-13 | olaptesed pegol (NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer® | multiple myeloma | 2a | Noxxon Pharma (Germany | Cancer - Oncology |
| 2014-06-13 | lexaptepid pegol (NOX-H94) | anemia associated with chronic disease as infections, cancers, autoimmune diseases and chronic kidney diseases | 2a | Noxxon Pharma (Germany) | Infectious diseases - Hematological diseases - Cancer - Oncology - Autoimmune diseases - Renal diseases - Kidney diseases |
| 2014-06-13 | olaptesed pegol (NOX-A12 anti-CXCL12/SDF-1 - CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer® | chronic lymphocytic leukemia |
2a | Noxxon Pharma (Germany) | Cancer - Oncology |
| 2014-06-13 | eltrombopag (Promacta™/Revolade™) | chronic immune (idiopathic) thrombocytopenic purpura (cITP) |
3 | GSK (UK) Ligand Pharmaceuticals (USA - CA) | Autoimmune diseases - Rare diseases |
| 2014-06-13 | HDM-SPIRE (house dust mite allergy product candidate) | house dust mite allergy |
2b | Circassia (UK) | Allergic diseases - Immunological diseases |
| 2014-06-12 | galunisertib (LY2157299) | hepatocellular carcinoma | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2014-06-12 | Kalydeco® (ivacaftor) | patients with cystic fibrosis (CF) who have the G551D mutation | 3 | Vertex Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2014-06-12 | Vyvanse® (lisdexamfetamine dimesylate) | Attention-Deficit Hyperactivity Disorder (ADHD) |
pediatric study | Shire (UK-USA) | Mental diseases - CNS diseases |
| 2014-06-12 | BAL30072 in combination with meropenem | infections with multidrug-resistant Gram-negative bacteria |
1 | Basilea Pharmaceutica (Switzerland) | Infectious diseases |
| 2014-06-12 | ozenoxacin | adult and paediatric patients with impetigo |
3 | Ferrer (Spain) | Infectious diseases - Dermatological diseases |
| 2014-06-11 | paquinimod (57-57) | systemic sclerosis |
Active Biotech (Sweden) | Rare diseases | |
| 2014-06-11 | brodalumab (AMG 827) | psoriatic arthritis |
2 | Amgen (USA) AstraZeneca (UK) | Autoimmune diseases |
| 2014-06-11 | Vascepa ® (icosapent ethyl) capsules | Vascepa® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. |
retrospective analysis | Amarin (USA - NJ) | Metabolic diseases - Cardiovascular diseases |
| 2014-06-10 | AZD5312 (ISIS-ARRx) | prostate cancer |
1 | AstraZeneca (UK) | Cancer - Oncology |
| 2014-06-10 | ALX-0061 | rheumatoid arthritis | 1-2 | Ablynx (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-06-10 | BioChaperone® Lispro U300 (ultra-fast acting formulation of insulin Lispro - Humalog®) | diabetes |
preclinical | Adocia (France) | Metabolic diseases |
| 2014-06-09 | Mitizax® (ALK HDM SLIT-tablet - immunotherapy tablet) | house dust mite induced hay fever and asthma | 3 | ALK (Denmark) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2014-06-09 | ISIS-DMPK Rx | myotonic dystrophy type 1 |
1 | Isis Pharmaceuticals (USA) | Rare diseases |
